CliffBio
small molecule

XARACOLL

BUPIVACAINE HYDROCHLORIDE

Loss of exclusivityJanuary 2033latest FDA-listed patent expiry
CompanyInnocoll Holdings →View the full company profile on CliffBio

Drug detail

Brand nameXARACOLL
Active ingredientBUPIVACAINE HYDROCHLORIDE
Strength100MG
Dosage formIMPLANT
RouteIMPLANTATION
ModalitySmall molecule
FDA approvalAugust 2020
Marketing statusDISCN

Listed patents

PatentExpiresType
11746141January 2033product
RE47826May 2029use U-2949

More from Innocoll Holdings

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XARACOLL patent cliff — loss of exclusivity January 2033 | CliffBio